Panel Provides Consensus for Standardizing CSCC Imaging

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Panel Provides Consensus for Standardizing CSCC Imaging

Latest News

Warning: Patient's Itchy Swollen Skin Patches Were Not Infectious Cellulitis

10-Year Data Back Early Start to Biologics in Arthritic Diseases

Shingles Recurrence or Something Worse?

Skin Problems, Kidney Complaints, and Venous Issues Spike During Heat Waves

First Oral Option for Dermatomyositis Gets FDA Green Light

A Call to End Routine Laboratory Monitoring for Patients on Isotretinoin

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Latest News

News All Time

US Regulators Urge More Research on Testosterone Therapy for Women as Experts Debate Benefits, Risks

FDA Grants Priority Review for Diabetic Foot Ulcer Therapy

Pennsylvania Measles Cases Top 700 After Four Outbreak-related Deaths Reported

Fear of Relapse Burdens Patients With Vitiligo

Adding IVIG to Prednisone Boosts Outcomes in IIMs

Smoke Exposure Tied to HS Risk in Children and Teens

A Decade After Mercury Ban, Toxic Skin Bleachers Still Offered on Top Retailers' Websites

Pennsylvania Measles-associated Deaths Climb to Four as Outbreak Grows

FDA Grants Priority Review to Zasocitinib for Psoriasis

Serious Infections Lower With Anifrolumab in CLE Patients

COVID, 6 Years on: The Pandemic’s Long Clinical Shadow

Prior Keratinocyte Carcinoma Tied to Mucosal Melanoma

Trust in Measles Vaccines Falls in US, Reuters Ipsos Poll Finds

Arizona Accuses L'Oreal Of Concealing Cancer Risks Linked to Hair Relaxers

Pembrolizumab Benefits Persist in Cervical Cancer

Criteria for Prescribing Testosterone: Who Qualifies?

Recommended News For You

Antibiotic Stewardship: Five Tips to Reduce Resistance

A researcher has found that yoga exhibits the "most improvement" in helping long-term cancer survivors restore their brain health.

Stop Calling It Cancer; The Alcohol Paradox; Rural Patients Lose Ground in Screening

Study Finds Microplastics Near Tumors; Experts Doubt Results

Fake Cancer Drugs; Let's Talk About Sex; Reducing Cancer-Related Fatigue

Long Wait Times on the Other Side of the Pond: King Charles' Cancer Diagnosis.

New analysis helps discern benign from malignant thyroid growths

Recommended Articles For You

Immune Ecosystem Remodeling Within Solid Tumor Niches

Unveiling the Mystery Behind Lymphovascular Invasion

Drug Safety Surveillance for Advanced Hematology Therapeutic Platforms

Unveiling the Mystery of Epstein-Barr Virus: What We Know So Far

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.